NCT05441618 (LYOPLACE) is a clinical trial of Lyoplant® in Tumor, Cerebral Ventricle, sponsored by Aesculap AG.

Who is sponsoring NCT05441618?

NCT05441618 is sponsored by Aesculap AG.

What drugs are being tested in NCT05441618?

Interventions in NCT05441618: Lyoplant®.

What condition does NCT05441618 study?

NCT05441618 studies Tumor, Cerebral Ventricle, Tumor, Cerebellar, Aneurysm Cerebral, Trauma, Brain.

Is NCT05441618 still recruiting?

NCT05441618 is currently completed. Last updated 13 January 2025.

Last reviewed 2025-01-13 · How we verify

NCT05441618: LYOPLACE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Post Market Clinical Follow-Up Study on the Performance and Safety of Lyoplant®

Completed Last updated 13 January 2025

What this trial tests

trial testing Lyoplant® in Tumor, Cerebral Ventricle in 50 participants. Completed in 10 January 2025.

Timeline

2 April 2024

Primary endpoint
19 December 2024

10 January 2025

Quick facts

Lead sponsor	Aesculap AG
Status	Completed
Study type	OBSERVATIONAL
Enrollment	50
Start date	2 April 2024
Primary completion	19 December 2024
Estimated completion	10 January 2025
Sites	1 location across Germany

Drugs / interventions tested

Lyoplant®

Conditions studied

Tumor, Cerebral Ventricle — all drugs for Tumor, Cerebral Ventricle →
Tumor, Cerebellar — all drugs for Tumor, Cerebellar →
Aneurysm Cerebral — all drugs for Aneurysm Cerebral →
Trauma, Brain — all drugs for Trauma, Brain →

Sponsor

Aesculap AG — full company profile →

Who can join

18 and older, any sex, with Tumor, Cerebral Ventricle or Tumor, Cerebellar. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Retrospective, single center, single arm PMCF study on the performance and safety of Lyoplant® used for the replacement and extension of connective tissue structures in neurosurgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Aesculap AG trials

Trials by the same sponsor.

NCT06298500 — Clinical Performance of HISTOACRYL® LAPFIX - CANNULA for Laparoscopic Inguinal Hernia Repair · completed
NCT05944081 — Postmarket Clinical Follow-Up Study on Arcadius XP L® Interbody Fusion Device · withdrawn
NCT06055946 — Symmcora® Long-term Bidirectional Barbed Suture for Anastomosis in Patients Undergoing Robot Assisted Radical Prostatect · completed
NCT05182320 — Study Measuring the Effects of Patient Data for Total Hip and Total Knee Arthroplasty Patients Using an APP Based Sensor · withdrawn
NCT06065800 — STEELEX® Sternum Set + BONE WAX® + STEELEX® Electrode Set in Patients Undergoing Cardiac Surgery · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05441618 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aesculap AG
Last refreshed: 13 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05441618.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing